SMIP004

Modify Date: 2024-01-10 16:33:07

SMIP004 Structure
SMIP004 structure
Common Name SMIP004
CAS Number 143360-00-3 Molecular Weight 205.29600
Density 1.003g/cm3 Boiling Point 343ºC at 760mmHg
Molecular Formula C13H19NO Melting Point N/A
MSDS N/A Flash Point 206.1ºC

 Use of SMIP004


SMIP004 is a novel inducer of cancer-cell selective apoptosis of human prostate cancer cells, it was found to downregulate SKP2 and to stabilize p27.IC50 Value: 1.09 uM (MTT assay in LNCaP-S14 cells) [1]Target: Apoptosis inducer; SKP2in vitro: Whereas SMIP012 and 016 were moderately toxic in normal fibroblasts, SMIPs 001 and 004 showed substantial cancer cell specificity being at least five times more potent in LNCaP-S14 than in IMR90 cells , treatment with either MG132 or SMIP004 increased p27 half-life to > 6 h [1]. Both SMIP001 and 004 led to a strong increase in the recruitment of p27 to CDK2, while SMIP001 also slightly increased coprecipitation of p21 (Figure 6c). SMIP004 also reduced the amounts of cyclins E and A retrieved with CDK2. This was paralleled by a marked downregulation of cyclins E and A upon SMIP004 treatment. SMIP004 decreased the levels of positive cell cycle regulators, upregulated cyclin-dependent kinase inhibitors, and resulted in G1 arrest, inhibition of colony formation in soft agar, and cell death [2].in vivo: SMIP004 potently inhibits the growth of prostate and breast cancer xenografts in mice [2].Clinical trial:

 Names

Name N-(4-butyl-2-methylphenyl)acetamide
Synonym More Synonyms

 SMIP004 Biological Activity

Description SMIP004 is a novel inducer of cancer-cell selective apoptosis of human prostate cancer cells, it was found to downregulate SKP2 and to stabilize p27.IC50 Value: 1.09 uM (MTT assay in LNCaP-S14 cells) [1]Target: Apoptosis inducer; SKP2in vitro: Whereas SMIP012 and 016 were moderately toxic in normal fibroblasts, SMIPs 001 and 004 showed substantial cancer cell specificity being at least five times more potent in LNCaP-S14 than in IMR90 cells , treatment with either MG132 or SMIP004 increased p27 half-life to > 6 h [1]. Both SMIP001 and 004 led to a strong increase in the recruitment of p27 to CDK2, while SMIP001 also slightly increased coprecipitation of p21 (Figure 6c). SMIP004 also reduced the amounts of cyclins E and A retrieved with CDK2. This was paralleled by a marked downregulation of cyclins E and A upon SMIP004 treatment. SMIP004 decreased the levels of positive cell cycle regulators, upregulated cyclin-dependent kinase inhibitors, and resulted in G1 arrest, inhibition of colony formation in soft agar, and cell death [2].in vivo: SMIP004 potently inhibits the growth of prostate and breast cancer xenografts in mice [2].Clinical trial:
Related Catalog
References

[1]. Rico-Bautista E, Yang CC, Lu L, Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells. BMC Biol. 2010 Dec 23;8:153.

[2]. Rico-Bautista E, Zhu W, Kitada S, Small Molecule-Induced Mitochondrial Disruption Directs Prostate Cancer Inhibition via UPR Signaling. Oncotarget. 2013 Jul 14.

 Chemical & Physical Properties

Density 1.003g/cm3
Boiling Point 343ºC at 760mmHg
Molecular Formula C13H19NO
Molecular Weight 205.29600
Flash Point 206.1ºC
Exact Mass 205.14700
PSA 29.10000
LogP 3.36900
Vapour Pressure 7.24E-05mmHg at 25°C
Index of Refraction 1.539
Storage condition 2-8℃

 Safety Information

HS Code 2924299090

 Customs

HS Code 2924299090
Summary 2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%

 Synonyms

acetic acid-(4-butyl-2-methyl-anilide)
Essigsaeure-(4-butyl-2-methyl-anilid)
Acetamide,N-(4-butyl-2-methylphenyl)
6-Acetamino-3-butyl-toluol
2-methyl-4-butylacetanilide
N1-(4-butyl-2-methylphenyl)acetamide
SMIP004